Riskpilot← Back to searchSign inGet full accessGlycoDisplay ApS
APSActiveCVR 38218603Blegdamsvej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20161 employees
Revenue 2024
DKK -277K
-22% vs 2023
EBITDA margin
113.3%
+20% vs 2023
Equity ratio
-188.4%
Financial strength
Net profit 2024
DKK -246K
+20% vs 2023
| Revenue | DKK -277K | -22% |
| EBITDA | DKK -314K | +20% |
| Net profit | DKK -246K | +20% |
| Total assets | DKK 644K | +24% |
| Equity | DKK -1,2M | -25% |
| Employees | 1 | — |
Legal name
GlycoDisplay ApS
CVR number
38218603
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30. november 2016
Share capital
DKK 100.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at udvikle nye lægemidler ved optimering af sukkerstrukturer og dermed beslægtet virksomhed.
Address
Blegdamsvej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -334 | 528 | -336 | -390 | 305 | -463 | -354 | -277 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -363 | 465 | -376 | -425 | 273 | -514 | -393 | -314 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -363 | 465 | -376 | -425 | 273 | -514 | -393 | -314 |
| Net financials | -2 | -2 | -0 | -22 | -6 | -1 | -0 | -1 |
| Profit before tax | -365 | 463 | -376 | -448 | 267 | -515 | -393 | -315 |
| Tax | -0 | 23 | -0 | -0 | -120 | -113 | -88 | -69 |
| Net profit | -365 | 441 | -376 | -448 | 387 | -402 | -305 | -246 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 511 | 822 | 564 | 289 | 935 | 521 | 518 | 644 |
| Equity | -265 | 176 | -200 | -647 | -260 | -662 | -968 | -1.213 |
| Long-term debt | 600 | 600 | 600 | 800 | 1.099 | 1.099 | 1.399 | 1.799 |
| Short-term debt | 175 | 46 | 163 | 137 | 96 | 84 | 87 | 59 |
| Total debt | 775 | 646 | 763 | 937 | 1.195 | 1.183 | 1.486 | 1.858 |
EBITDA margin
-31393400.0%
This company
15.8%
Market median
-198692505% vs market
20172024
Equity ratio
-188.4%
This company
38.2%
Market median
-593% vs market
20172024
Return on equity
-24566800.0%
This company
18.4%
Market median
-133515317% vs market
20172024
Net profit margin
-24566800.0%
This company
8.1%
Market median
-303293927% vs market
20172024
Asset turnover
-0.43×
This company
1.12×
Market median
-138% vs market
20172024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-11-30 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HC Management | Management | 2016 | — | — |
CK Management | Management | 2016 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
GLYCOZYM ApS | Company | 50.0% | 50.0% | 2016 |
Anceli Holding ApS | Company | 10.0% | 10.0% | 2016 |
| Individual | 10.0% | 10.0% | 2016 | |
| Individual | 10.0% | 10.0% | 2016 | |
Mandel & Clausen Holding ApS | Company | 10.0% | 10.0% | 2016 |
GeCo ApS | Company | 5.0% | 5.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GLYCOZYM ApS
GlycoDisplay ApS Board members of GlycoDisplay ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Clausen | Management | 0 companies |
| Claus Kristensen | Management | 0 companies |